Ocular Itch Associated With Allergic Conjunctivitis

ZERVIATE® with Hydrella® is the first and only ocular formulation of cetirizine (active ingredient in ZYRTEC®)1,2 designed to alleviate ocular itch associated with allergic conjunctivitis in your moderate to severe patients.1,3 ZERVIATE® safely delivers a rapid 3-minute onset of action and 8-hour duration,1,3 while the Hydrella® system provides comfort with each drop. INITIATE ZERVIATE®.*,4

Eyevance® Pharmaceuticals LLC has been acquired by Santen Pharmaceutical Co., Ltd. ZERVIATE® is a registered trademark of Eyevance Pharmaceuticals.
*All other trademarks are the property of their respective owners.

References:

  1. ZERVIATE [package insert]. Fort Worth, TX: Eyevance Pharmaceuticals LLC; 2020
  2. US Department of Health and Human Services, Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. (Orange Book). 40th ed. Washington, DC: USDepartment of Health and Human Services, Food and Drug Administration; 2020
  3. Meier EJ, Torkildsen GL, Gomes PJ, et al. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. Clin Ophthalmol. 2018;12:2617-2628.
  4. Malhotra RP, Meier E, Torkildsen G, et al. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects. Clin Ophthalmol. 2019;13:403-413.

INDICATIONS AND USAGE
ZERVIATE® (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis.

DOSAGE AND ADMINISTRATION
Instill one drop of ZERVIATE in each affected eye twice daily (approximately 8 hours apart).

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Contamination of Tip and Solution: As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container to avoid injury to the eye and to prevent contaminating the tip and solution. Keep the multi-dose bottle closed when not in use. Discard the single-use container after using in each eye.
Contact Lens Wear: Patients should be advised not to wear a contact lens if their eye is red. ZERVIATE should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of ZERVIATE. The preservative in ZERVIATE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIATE.

ADVERSE REACTIONS
The most commonly reported adverse reactions occurred in approximately 1%–7% of patients treated with either ZERVIATE or vehicle. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced.

Please see the Full Prescribing Information.

Global Research & Development
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved